SAN DIEGO, Sept. 8 /PRNewswire/ -- Cyntellect, Inc., a privately-held biotechnology company based in San Diego, California, announced today that the Company’s Laser-Enabled Analysis and Processing (“LEAP”) System is in conformance with the European Union’s (EU) directives for CE marking. The CE mark identifies a product as complying with applicable EU health and safety requirements, thereby enabling product sales in the EU.
Simultaneously, the Company also announced that it has shipped a LEAP System to a major pharmaceutical company customer in Europe, the first such commercial delivery to the EU.
“CE marking of LEAP represents a major commercial milestone for Cyntellect and opens up an important market for our products,” stated Fred Koller, Ph.D., Cyntellect’s President and Chief Technical Officer. “We are pleased and proud to meet this goal and simultaneously ship our first commercial LEAP system to a major pharmaceutical company customer in Europe.”
LEAP is an automated instrument that combines high-speed optical imaging of cells, real-time image analysis and high-speed laser manipulation of individual live cells presented in microplate formats. Using LEAP, researchers can rapidly and selectively laser-irradiate specific cells achieving >99.9% purity. The in situ processing nature means researchers can exploit rare cell populations or cells that are typically refractory to currently available purification technologies (e.g. primary cells, patient cells or delicate cell lines) as well as more robust commonly used cell types. LEAP-based laser manipulation of cells has also been demonstrated to effectively permeabilize cells transiently without inducing cellular toxicity. This approach, called LaserFect(TM), enables introduction of a wide variety of biomolecules including ions, siRNAs, proteins and quantum dots, many of which cannot be transfected using current technologies.
About Cyntellect
Cyntellect, Inc. is a biotechnology company committed to [revolutionizing] the use of living cells in life science research, biopharmaceutical manufacturing and cellular therapy. Cyntellect combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information about Cyntellect, please visit its website at www.cyntellect.com.
Source: Cyntellect, Inc.
